Isolated limb perfusion with tumor necrosis factor α and melphalan for locally advanced soft tissue sarcoma: The value of adjuvant radiotherapy

Annals of Surgical Oncology

Volumn 13, Issue 4, 2006, Pages 518-524

  Thijssens, Katja M J ^a   Van Ginkel, Robert J ^a   Pras, Elisabeth ^a   Suurmeijer, Albert J H ^a   Hoekstra, Harald J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Isolated limb perfusion; Long term results; Melphalan; Radiotherapy; Sarcoma; Tumor necrosis factor

Indexed keywords

MELPHALAN; TASONERMIN; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; AGED; ANGIOSARCOMA; ARTICLE; CALCULATION; CANCER RECURRENCE; CANCER RELAPSE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CHONDROSARCOMA; CONTROLLED STUDY; DIAGNOSTIC VALUE; EPITHELIOID SARCOMA; FEMALE; FIBROMYXOSARCOMA; FIBROSARCOMA; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; LEIOMYOSARCOMA; LIMB PERFUSION; LONG TERM CARE; MALE; METASTASIS; MYXOID CHONDROSARCOMA; MYXOSARCOMA; NERVE SHEATH TUMOR; SCORING SYSTEM; SOFT TISSUE SARCOMA; STATISTICAL SIGNIFICANCE; SURGICAL TECHNIQUE; SYNOVIAL SARCOMA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; EXTREMITIES; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; LIMB SALVAGE; MALE; MELPHALAN; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RADIOTHERAPY, ADJUVANT; SARCOMA; SOFT TISSUE NEOPLASMS; SURVIVAL ANALYSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33644971604     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/ASO.2006.02.005     Document Type: Article

References (23)

1. Singer S, Demetri GD, Baldini EH, Fletcher CDM. Management of soft-tissue sarcomas: an overview and update. Lancet Oncol 2000; 1:75-85.
2. Eggermont AM, Schraffordt Koops H, Klausner JM. et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 1996; 224:756-64; discussion 764-5.
3. Van Ginkel RJ, Thijssens K, Pras E, van der Graaf WTA, Suurmeijer AJH, Hoekstra HJ. Isolated limb perfusion with TNF and melphalan for locally advanced soft tissue sarcoma; three time periods at risk for amputation (abstract). Ann Surg Oncol 2004; 11:S54.
4. Fletcher CDM, Unni KK, Mertens F, (eds). World Health Organisation: Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon: IARC Press, 2002.
5. Guillou L, Coindre JM, Bonichon F, et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol 1997; 15:350-62.
6. Hogeboom WR, Hoekstra HJ, Mooyaart EL, Freling NJ, Schraffordt Koops H. MRI or CT in the preoperative evaluation of soft-tissue tumors. Arch Orthop Trauma Surg 1991; 110:162-4.
7. Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual. 6th ed. New York: Springer-Verlag, 2002.
8. Fontijne WP, Mook PH, Schraffordt Koops H, Oldhoff J, Wildevuur CR. Improved tissue perfusion during pressure regulated hyperthermic regional isolated perfusion: a clinical study. Cancer 1985; 55:1455-61.
9. Schraffordt Koops H, Oldhoff J, Oosterhuis JW, Beekhuis H. Isolated regional perfusion in malignant melanoma of the extremities. World J Surg 1987; 11:527-33.
10. Daryanani D, Komdeur R, Ter Veen J, Nijhuis PH, Piers DA, Hoekstra HJ. Continuous leakage measurement during hyperthermic isolated limb perfusion. Ann Surg Oncol 2001; 8:564-5.
11. World Health Organisation: Handbook for Reporting Results of Cancer Treatment. Geneva: WHO Offset Publication, 1979.
12. Kaplan EL, Meier P. Nonparametric estimates from incomplete observations. J Am Stat Assoc 1958; 53:457-81.
13. Williard WC, Hajdu SI, Casper ES, Brennan MF. Comparison of amputation with limb-sparing operations for adult soft tissue sarcoma of the extremity. Ann Surg 1992; 215:269-75.
14. Pisters PW, Harrison LB, Leung DH, Woodruff JM, Casper ES, Brennan MF. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol 1996; 14:859-68.
15. Rosenberg SA, Tepper J, Glatstein E, et al. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg 1982; 196:305-15.
16. Yang JC, Chang AE, Baker AR, et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 1998; 16:197-203.
17. Fein DA, Lee WR, Lanciano RM, et al. Management of extremity soft tissue sarcomas with limb-sparing surgery and postoperative irradiation: do total dose, overall treatment time, and the surgery-radiotherapy interval impact on local control? Int J Radiat Oncol Biol Phys 1995; 32:969-76.
18. Olieman AF, Pras E, van Ginkel RJ, Molenaar WM, Schraffordt Koops H, Hoekstra HJ. Feasibility and efficacy of external beam radiotherapy after hyperthermic isolated limb perfusion with TNF-alpha and melphalan for limb-saving treatment in locally advanced extremity soft-tissue sarcoma. Int J Radiat Oncol Biol Phys 1998; 40:807-14.
19. Trovik CS, Bauer HC, Berlin O, et al. Local recurrence of deep-seated, high-grade, soft tissue sarcoma: 459 patients from the Scandinavian Sarcoma Group Register. Acta Orthop Scand 2001; 72:160-6.
20. Lin PP, Boland PJ, Healy JH. Treatment of femoral fractures after irradiation. Clin Orthop Relat Res 1998; 352:168-78.
21. O'Sullivan B, Davis AM, Turcotte R, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet 2002; 359:2235-41.
22. Lans TE, Grunhagen DJ, de Wilt JHW, van Geel AN, Eggermont AMM. Isolated limb perfusions with TNF and melphalan for locally recurrent soft tissue sarcoma in previously irradiated limbs. Ann Surg Oncol 2005; 12:406-11.
23. van Ginkel RJ, Hoekstra HJ, Pruim J, et al. FDG-PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma. J Nucl Med 1996; 37:984-90.